The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-10

Study Completion Date

2017-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours. Part A will assess the single and multiple dose pharmacokinetics of olaparib monotherapy and multiple dose pharmacokinetics of olaparib in combination with paclitaxel. Part B will assess the safety of multiple doses of olaparib in Cohort 1 and of olaparib when co-administered with paclitaxel in Cohort 2

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

NCT01894256

Solid Tumours

COMPLETED PHASE1

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

NCT02640755

Solid Malignancies

COMPLETED PHASE1

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT01894243

Solid Tumours

COMPLETED PHASE1

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

NCT03553108

Malignant Solid Tumor

COMPLETED PHASE1

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Part A will access the pharmacokinetics of olaparib: Cohort 1 will investigate the single and multiple dose pharmacokinetics of olaparib following 300mg bd monotherapy dose(s); Cohort 2 will investigate the single and multiple dose pharmacokinetics of olaparib following 100mg bd monotherapy dose(s) and the multiple dose pharmacokinetics in the presence of co-administered paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle).

In Part B: Safety profile of olaparib 300mg bd as monotherapy and olaparib 100mg bd in combination with weekly paclitaxel will also be investigated in Chinese patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumours

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day

Group Type EXPERIMENTAL

Olaparib

Intervention Type DRUG

Tablet-150mg, Oral

Cohort 2

Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)

Group Type EXPERIMENTAL

Paclitaxel

Intervention Type DRUG

Injection

Olaparib

Intervention Type DRUG

Tablet-100mg, Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olaparib

Tablet-150mg, Oral

Intervention Type DRUG

Paclitaxel

Injection

Intervention Type DRUG

Olaparib

Tablet-100mg, Oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of fully informed consent
2. Patient aged ≥ 18 years
3. Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy and for which no suitable effective standard therapy exists
4. life expectancy of ≥ 12 weeks
5. Patients for Cohort 2 must be eligible for paclitaxel treatment
6. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
7. ECOG performance status ≤ 2
8. Satisfactory organ and bone marrow function measured within 28 days prior to administration of study treatment including - Haemoglobin ≥ 10.0 g/dL and no blood transfusion in the 4 weeks prior to the first dosing of study drug. - Absolute neutrophil count ≥ 1.5 × 109/L
9. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1.
10. Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.

Exclusion Criteria

1. Involvement in the planning and/or conduct of the study.
2. Previous enrolment in the present study.
3. Treatment with any investigational product during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
4. Any previous treatment with a Poly (ADP-ribose) polymerase (PARP) inhibitor, including olaparib.
5. Patients with other malignancy within the last 5 years, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, ductal carcinoma in situ, Stage 1, Grade 1 endometrial cancer, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
6. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. These include patients with gastric or intestinal cancer or patients with prior surgical procedures such as full or partial gastrectomy.
7. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study treatment.
8. Concomitant use of known potent CYP3A4 (Cytochrome P450 3A4) inhibitors.
9. Patients with any ongoing toxicities (\>CTCAE (Common Terminology Criteria for Adverse Events) grade 2), with the exception of alopecia, caused by previous cancer therapy.
10. Resting ECG with QTc (Heart Rate Corrected QT interval) \> 470msec or family history of long QT syndrome.
11. Patients with interstitial pneumonia or diffused symptomatic fibrosis of the lungs.
12. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
13. Patients with symptomatic uncontrolled brain metastases.
14. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
15. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
16. Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).
17. Patients with known active hepatic disease (i.e. Hepatitis B or C).
18. Patients with a known hypersensitivity to olaparib, paclitaxel or any of the excipients of the product.
19. Breastfeeding women.
20. Clinical judgement by the investigator that the patient should not participate in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No